SRR493955
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- PROTEIN_SECRETION+0.380
- HYPOXIA+0.320
- ANGIOGENESIS+0.290
- TGF_BETA_SIGNALING+0.290
- G2M_CHECKPOINT+0.230
- HEDGEHOG_SIGNALING+0.230
- E2F_TARGETS+0.190
- PANCREAS_BETA_CELLS+0.190
- MYOGENESIS+0.170
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.320
- MYC_TARGETS_V2-0.310
- ALLOGRAFT_REJECTION-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- INTERFERON_ALPHA_RESPONSE-0.280
- IL2_STAT5_SIGNALING-0.270
- TNFA_SIGNALING_VIA_NFKB-0.260
- OXIDATIVE_PHOSPHORYLATION-0.230
- INFLAMMATORY_RESPONSE-0.190
- XENOBIOTIC_METABOLISM-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DQ-5631-01A-01R-1873-07 | — | — | 0.805 |
| 2 | 20120162.TNBC | — | E | 0.767 |
| 3 | GSM6454737 | — | D | 0.749 |
| 4 | SRR25617936 | — | E | 0.748 |
| 5 | 20110025.TNBC | — | E | 0.741 |
| 6 | 20020076.Her2HRpos | — | C | 0.737 |
| 7 | SRR5088885 | — | — | 0.722 |
| 8 | SRR1313136 | — | E | 0.721 |
| 9 | TCGA-P3-A5QA-01A-11R-A28V-07 | — | — | 0.717 |
| 10 | TCGA-BH-A1EV-01A-11R-A137-07 | — | C | 0.714 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |